Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million Leiden, The Netherlands, July 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today confirmed that on July 3 (one year following the closing of its IPO), it filed a shelf registration statement with the US Securities and Exchange Commission. The filing of the registration statement is not an offering to sell securities and is intended to enable Prosensa the flexibility to raise up to $150 million in one or more offerings while the shelf registration statement is effective, if the company chooses to do so. The specific terms of any securities that the Company may offer, if it chooses to do so, will be determined at the time of such offering and will be described in a separately filed prospectus supplement at the time of such offering. The shelf registration statement also includes the shares of Prosensa's three largest shareholders. There are no immediate plans to offer or sell securities under the shelf registration statement. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer of these securities will be made solely by means of the prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. When available, copies of the prospectus and any accompanying prospectus supplement relating to and describing the terms of the offering may be obtained from Prosensa Holding N.V., J.H. Oortweg 21, 2333 CHLeiden, The Netherlands, Attention: Celia Economides; firstname.lastname@example.org. About Prosensa Holding N.V. Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, Myotonic dystrophy and Huntington's disease.www.prosensa.com About DMD Duchenne muscular dystrophy (DMD) is a severely debilitating childhood neuromuscular disease that affects up to 1 in 3,500 live male births. This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of the dystrophin protein. As a result, patients suffer from progressive loss of muscle strength, often rendering them wheelchair-bound before the age of 12. Respiratory and cardiac muscle can also be affected by the disease and most patients die in early adulthood due to respiratory and cardiac failure. Forward Looking Statement This press release contains certain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding any future offering under the shelf registration statement are forward-looking statements. Such forward-looking information involves risks and uncertainties that could significantly affect expected results. These risks and uncertainties are discussed in the Company's SEC filings, including, but not limited to, the Company's annual report on Form 20-F. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. CONTACT: Prosensa Holding N.V. Celia Economides M: +1 917.941.9059 M: +31 (0) 64 85 18 182 (NL) E: email@example.com Prosensa Holding B.V. Logo
Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million
Press spacebar to pause and continue. Press esc to stop.